ZEISS, Mindpeak Working Together on Integrated Pathology Solution

ZEISS is partnering with Mindpeak to develop an integrated Multiplex Immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications.

“Mindpeak’s established product portfolio of clinical AI algorithms, which currently supports pathologists in assessing immunohistochemistry (IHC), hematoxylin and eosin (H&E) stained slides, will be extended to mIF in this promising partnership,” Mindpeak CEO Felix Faber said. “We are thrilled to combine our expertise in AI pathology with ZEISS’s instrumentation to create a streamlined workflow from slide to report for our customers.”

Mindpeak’s expertise in artificial intelligence (AI)-based image analysis of pathological tissues— particularly through its established algorithms for clinical routine applications—complements ZEISS’s advanced instruments and software for mIF research applications. The joint solution will integrate both companies’ existing offerings to enhance the value for users and address multiple market segments, including:

• Research: Providing advanced mIF tools for scientific exploration
• Diagnostic and Companion Diagnostic Development: Empowering personalized medicine initiatives
• Clinical Routine: Offering reliable, AI-powered tools for everyday pathological assessments.

“At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Mindpeak marks a significant milestone in advancing workflows for translational and clinical pathology,” stated Michael Albiez, head of ZEISS Research Microscopy Solutions. “Together, we are introducing an integrated solution that streamlines mIF workflows and improves reproducibility to meet the evolving needs of both translational research and clinical settings. By combining ZEISS’ imaging expertise with Mindpeak’s AI-driven analytics, we aim to enable researchers and clinicians to gain deeper insights with greater efficiency and precision.”

The partnership combines complementary competencies and expands both companies’ reach in the growing mIF market.

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care.

ZEISS is an international technology enterprise operating in the optics and optoelectronics sectors. In FY 2023, the ZEISS Group generated €10 billion in annual revenue in its four segments: Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets.

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. ZEISS is also synonymous with lithography optics, which are used by the chip industry to manufacture semiconductor components.

With a portfolio aligned with future growth areas like digitalization, healthcare and smart production and a strong brand, ZEISS is advancing optics and related fields with its solutions. ZEISS invests 15% of its revenue in R&D; it employs more than 44,000 workers, and is active globally in about 50 countries with more than 60 sales and service locations, 35 R&D facilities, and 35 production plants worldwide. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to promoting science, solely owns the holding company, Carl Zeiss AG.

ZEISS Research Microscopy Solutions provides light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises products and services for life sciences, materials, and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, the U.K., United States, and China.